Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to ovarian reserve parameters, namely AFC and AMH (study 2).
DOI:
https://doi.org/10.30574/gscbps.2020.13.2.0322Keywords:
Anti-Mullerian Hormone (Amh), Antral Follicle Count (Afc), Age Groups, Igf-1 Profile, Igfbp-3/ Igf-1 Ratio (Igf Ratio), Assisted Reproductive Technology (Art), In Vitro Fertilization (Ivf), Growth Hormone (Gh), PIVET Fsh-Dosing Algorithm.Abstract
This is the second of five studies undertaken on women preparing for assisted reproduction, to sequentially examine the relevance of the insulin-like growth factor (IGF) profile (IGF-1, IGFBP-3 and the IGFBP-3/ IGF-1 ratio) which, in children, provides the essential criteria to identify the GH-deficient individual. Whilst our first, published study, focussed on clinical parameters, this study examines its relevance to the two parameters which define the ovarian reserve. The first, that of the antral follicle count (AFC), shows highly significant, sequential changes across 4 age groups ranging from high counts in the younger women <35 years and low counts in the older women, namely those aged 35-39 years, those aged 40-44 years and those aged ≥45 years (p<0.0001). Similarly, the serum levels of anti-Mullerian hormone (AMH), a later introduced marker of ovarian reserve, also showed highly significant sequential changes across the 4 age groups with high levels recorded in the young women and low counts in the older women (p<0.0001). At the higher AFC range, concordance between AFC groups and AMH groups was high at r=0.79 for precise matching and r=0.95 when neighbouring groups were included. The correlation was also clear with inter-quartile AMH levels ranging 27 pmol/L to 50 pmol/L across the higher AFC groups and 8 pmol/L to 10 pmol/L in the lowest groupings. However, IGF profiles showed no significant variations across the entire range, neither for the AFC nor for the AMH groups. Our next study will report on the relevance of the IGF profile to clinical outcomes.
Metrics
References
Yovich JL, Craft IL. Founding pioneers of IVF: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol, 2018; 18:317-323, doi.org/10.1016/J.repbio.2018.11.004
Yovich JL. Founding pioneers of IVF Update: Independent innovative researchers generating livebirths within 4 years of the first birth. Reprod Biol, 2020; 20:111-113, doi.org/10.1016/j.repbio.2019.12.008
Yovich JL, Ye Y, Regan SLP, Keane KN. The evolving concept of poor-prognosis for women undertaking IVF and the notion of growth hormone as an adjuvant; a single-center viewpoint. Front Endocrinol, 2019; 10:808; pp14, doi.org/10.3389/fendo.2019.0080
Farquhar C. Add-ons for assisted reproductive technology: can we be honest here? Fertil Steril, 2019; 112(6):971-972. doi.org/10.1016/j.fertnstert.2019.10.010
Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril, 2018; 110:1298–309, doi: 10.1016/j.fertnstert.2018.08.018
Yovich JL, Regan SL, Zaidi SN, Keane KN. The concept of growth hormone deficiency affecting clinical prognosis in IVF. Front Endocrinol, 2019; 10:650, Pp9, doi: 10.3389/fendo.2019.00650
Bortoletto P, Spandorfer S. Growth hormone: in search of the holy grail for poor responders (or a felony). Fertil Steril, 2020; 114(1):63-64, doi.org/10.1016/j.fertnstert.2020.04.012
Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes, 2012; 19(1):47-52, doi:10.1097/MED.0b013e32834ec952
Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth Hormone and insulin-like growth factor in reproductive tissues. Front Endocrinol, 2019; 10:777, pp14, doi: 10.3389/fendo.2019.00777
Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction; relationship to clinical parameters (Study 1). J Pers Med, 2020; 10(3)122:1-15, doi.org/10.3390/jpm10030122
Yovich JL. How to prepare the egg and embryo to maximise IVF success. In: Monitoring the stimulated IVF cycle. Section II: Stimulation for IVF (Eds: Gabor T Kovacs, Anthony J Rutherford and David K Gardner). Cambridge University Press, Cambridge U.K., 2019; 94-120, doi: 10.1017/9781316756744
Yovich J, Stanger J, Hinchliffe P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online, 2012; 24(3):281-292, doi:10.1016/j.rbmo.2011.11.014
Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. (2016). PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther, 10, 2561–573, doi: 10.2147/DDDT.S104104
Keane K, Cruzat VF, Wagle S, Chauhary N, Newsholme P, Yovich J. Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome. Reprod Biol, 2017; 17:51-59, doi.org/10.1016/j.repbio.2016.12.002
Hammer Ø, Harper DAT, Ryan PD. PAST: paleontological statistics software package for education and data analysis. Palaentologia Electronica, 2001; 4(1): 9pp
Nasioudis D, Minis E, Irani M, Kreines F, Witkin SS, Spandorfer SD. Insulin-like growth factor-1 and soluble FMS-like tyrosine kinase-1 prospectively predict cancelled IVF cycles. J Assist Reprod Genet, 2019; 36(12):2485-2491, doi: 10.1007/s10815-019-01618-3.
Man L, Lekovich J, Canon C, Rosenwaks Z, James D. Cycle day-2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor responders. Fertil Steril, 2020; 113:1205-1214, doi.org/10.1016/j.fertnstert.2020.02.111.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.